Jim Cramer says Roche's $8.3 billion bid for U.S. biotech firm InterMune means big pharma is thinking big. Cramer says there are so many biotech companies out there losing money as InterMune was, while at the same time companies like Roche, Merck, Pfizer and Glaxo need to make acquisitions for growth. He says the game plan for these companies is to find a biotech that may have a drug breakthrough and is about to get FDA approval. In this case, Roche, the Swiss drugmaker, is hoping to cash in on the pending U.S. approval of California-based InterMune's new drug that treats a deadly lung disease. Roche says it will continue to focus on targeted acquisitions.

More from Video

Stock Market Just Took Another Beating -- Here's What You Need to Know

Stock Market Just Took Another Beating -- Here's What You Need to Know

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

Dunkin' Donuts Should Just Sell Itself Already

Dunkin' Donuts Should Just Sell Itself Already

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Intel CEO Out After Past Relationship With Staffer - Why Stock Is Now in Play

Intel CEO Out After Past Relationship With Staffer - Why Stock Is Now in Play